Feb 10 (Reuters) - The U.S. Food and Drug Administration will not review Moderna's approval application for its influenza vaccine, the company said on Tuesday, sending its shares down 8% in ...
Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory ...
On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...
Moderna’s announcement quoted the language the FDA used when approving the company’s clinical trial protocol in 2024. The agency had originally suggested that for people age 65 and older, the company ...
The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The news is the ...
Update: The FDA reversed its decision on Feb. 18 and agreed to consider Moderna's application. Read the latest here. Our earlier story is below. The Food and Drug Administration is refusing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results